Table 1 Efficacy of PTX-based chemotherapy for advanced esophageal cancer
Authors | Cases (SC/AC/other) | Chemotherapy | Efficacy | ||
|---|---|---|---|---|---|
Total | SC | AC | |||
van der Gaast, et al. [20] | 31(NA/NA) | PTX 100–160 mg/m2 iv3h, d1; DDP 60 mg/m2, d1, q2w | 55% | 53% | 60% |
Kelsen, et al. [21] | 37(27/10) | PTX 200 mg/m2, civ24h, d1; DDP 75 mg/m2, d1, q3w | 49% | 60% | 44% |
Polee, et al. [22] | 51(16/31/4) | PTX 180 mg/m2, iv3h, d1; DDP 60 mg/m2, d1, q2w | 43% | 39% | 44% |
Huang, et al. [23] | 30(30/0) | PTX 175 mg/m2, iv3h, d1; DDP 40 mg/ m2, d2, 3, q3w | 59% | 59% | – |
Ilson, et al. [24] | 61(31/30) | PTX 175 mg/m2 iv3h, d1; DDP 20 mg/m2 5d; 5-FU 1 g/m2/d, 5d; q3w | 48% | 50% (CR 20%) | 46%(CR 3%) |
Lin, et al. [25] | 41(41/0) | PTX 35 mg/m2, d1, 4, 8, 11, DDP 20 mg/m2, d2, 5, 9, 12; 5-FU 2 g/m2, q3w | 39% | 39% | – |